U.S. markets open in 7 hours 57 minutes

Amgen Inc. (AMGN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
285.18+1.72 (+0.61%)
At close: 04:00PM EST
284.00 -1.18 (-0.41%)
After hours: 08:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close283.46
Bid0.00 x 800
Ask0.00 x 1800
Day's Range281.39 - 285.72
52 Week Range211.71 - 329.72
Avg. Volume2,750,458
Market Cap152.833B
Beta (5Y Monthly)0.62
PE Ratio (TTM)22.83
EPS (TTM)12.49
Earnings DateApr 25, 2024 - Apr 29, 2024
Forward Dividend & Yield9.00 (3.17%)
Ex-Dividend DateFeb 15, 2024
1y Target Est307.59
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
-14% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for AMGN

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Amgen Inc.
    Analyst Report: Amgen Inc.Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
    Fair Value
    Economic Moat
    15 days agoMorningstar
View more
  • Insider Monkey

    13 Best Dow Jones Dividend Stocks According to Analysts

    In this article, we discuss 13 best Dow Jones dividend stocks according to analysts. You can skip our detailed analysis of dividend stocks in the Dow and their performance over the years, and go directly to read 5 Best Dow Jones Dividend Stocks According to Analysts. Investors have employed various dividend strategies over time to […]

  • Zacks

    BeiGene (BGNE) to Report Q4 Earnings: What's in the Cards?

    BeiGene's (BGNE) revenues in fourth-quarter 2023 are expected to have been driven by the sales of its marketed pharmaceutical products.

  • PR Newswire


    Amgen (NASDAQ:AMGN) will host a webcasted call at 1:00 p.m. PT on Thursday, February 22, 2024 to discuss Rare Disease, its newly added fourth pillar of growth, and provide insights on its rare disease strategy and opportunities, including marketed products and pipeline. Murdo Gordon, executive vice president of Global Commercial Operations at Amgen, Jay Bradner, executive vice president of Research and Development and chief scientific officer at Amgen, Vikram Karnani, executive vice president of